Every specimen tells a story. We reveal the biology behind it.
10M+
Biospecimens sourced from nearly 100 global clinical sites
2,000+
Clinical trial programs supported, with ~300 active today
1,150+
biopharma customers — including every top 25 and every leading CDx IVD kit manufacturer.
Three entry points into the biomarker continuum, each backed by the same scientific and operational standard.
For researchers and procurement teams sourcing samples
For researchers and procurement teams sourcing samples
One of the world’s largest commercial biobanks of normal and diseased biospecimens — standalone or matched, on the shelf or collected prospectively across 100+ global sites. Every sample is characterized, quality-checked, and ready to trust.
For scientific and clinical teams
For scientific and clinical teams
Discovery delivers molecular pathology, genomics, proteomics, and clinical flow cytometry services from early discovery through Phase III, in CLIA/CAP-accredited, GCLP-compliant labs. Our senior scientists and pathologists shape feasibility and biomarker strategy early enough to change a program’s course, not just validate it.
For program leads building biomarker-driven development plans
For program leads building biomarker-driven development plans
We take an integrated approach to support end-to-end biomarker programs from target identification through assay development, clinical trial execution, and CDx launch. With IVDR Health Institution status in Kassel, Germany, we accelerate EU study timelines to just 6–8 months.
Customer perspective
“As a clinical researcher focusing on oncology, the high-quality, well-annotated patient biospecimens from Discovery Life Sciences have significantly accelerated our research progress. The samples we received are of high quality with complete clinical data, which provides a solid foundation for our studies on tumor heterogeneity and therapeutic resistance.”
“The quality of AllCells products is impressive. I have had high yield of the cell types I have been using. In addition, the customer service has been beyond compare. I truly appreciate working with the personnel directly and it sure has been smooth.”
“Speed. I asked for a quote, received it the same day. I needed some changes and they were actioned the following day. I sent a PO and the next day the products were sent out. Fantastic speed of service.”
Biomarker programs focus on some of the most complex and patient-impacting areas of medicine, including oncology, immunology, and cell and gene therapy. Discovery brings deep scientific expertise and tailored capabilities to each disease area and therapeutic modality.
Discovery’s AllCells® solutions provide high-quality healthy human tissues and cells, including leukopaks, bone marrow, and isolated immune cells. Backed by deep leukapheresis expertise and a highly reliable donor network, we support CGT programs from early research through commercial manufacturing with a 98% delivery success rate.
Discovery holds the industry’s most extensively characterized oncology biospecimen inventory, and the lab services to make sense of it. Whether the samples are yours or ours, we carry oncology programs from biomarker discovery through companion diagnostics.
“Only the DLS team were able to deliver robust and specific assay… a data package with scoring intensities for 178 patient samples across 13 cancer indications.”
Eric Tam, PhD, Senior Director of Research, EvolveImmune Therapeutics
ADCs, Bispecifics, and other programs depend on biomarker precision — from target expression and mechanism of action to off-tumor toxicity. Discovery combines pathologist-led expertise with multi-omic workflows across established and emerging targets, so your program carries the biomarker evidence it needs from discovery through clinical development.
Discovery provides high-quality immune-relevant biospecimens, including PBMCs and isolated immune cell subsets from diagnosed patients and normal donors, along with multi-omics services that enable precise immunophenotyping and functional immune analysis. Our expertise has powered programs across inflammation, autoimmunity, and other immune-mediated disorders.
Access to neurologically characterized biospecimens, CSF, and matched biofluid sets, paired with the proteomics depth required for biomarker discovery in neurodegenerative disease. Discovery brings sample relevance and analytical rigor to one of the hardest areas in biopharma.
Discovery also supports inflammation, metabolic, cardiology, and dermatology programs with the same biospecimen access, biomarker capability, and operational rigor.
Discovery’s latest work in the field: research, events, partnerships, and conversations shaping where precision medicine goes next.
From sample to insight, we bring the expertise to help get you there.
